secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2023-01-17T23:59:59+00:00
Accession:  0001493152-23-001536
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AIM ImmunoTech enters into clinical research agreement with AstraZeneca and Erasmus MC for pancreatic cancer study
--------------------------------------------------------------------------------

- Collaboration to evaluate Ampligen (rintatolimod) combined with AstraZeneca's durvalumab in metastatic pancreatic ductal adenocarcinoma.
- Erasmus MC will sponsor and conduct a phase II, non-randomized, open-label, single-arm study (DURIPANC Study).
- AIM supplies rintatolimod; AstraZeneca supplies durvalumab; AIM retains all intellectual property rights.
- Erasmus owns study data but grants AIM unrestricted use; AIM owns inventions related to rintatolimod.
- Agreement terminable on completion, material breach, insolvency, or ethics committee rejection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315223001536/0001493152-23-001536-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315223001536/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-001536

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer